Stakeholders: Diverse Trials Can Strengthen Understanding Of Drugs

FDA's draft guidance for diversity action plans in clinical trials can lead to better medications and mitigate risk with more inclusion leading to a better ability for drug companies to track adverse events in more demographics, some pharmaceutical industry stakeholders say. Increasing diversity may also lead to breakthrough therapies for conditions with small patient populations, according to a leading rare disease patient advocacy group. However, several commenters on FDA’s draft guidance warned its enrollment goals may be unrealistic for at...